Loading
A phase 2 trial of cabozantinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity is a phase 2, interventional study registered as NCT01639508 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 86 participants, started 2012-07 and due to reach its primary completion in 2027-07. Interventions recorded: Cabozantinib. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: objective response rate (ORR) (Group A); objective response rate (ORR) (Group B). Lung eligibility wording from the registry: "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Exelixis, Cabozantinib, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares RET fusion-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ROS1-positive non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.